Up-regulates VEGF-R2 / NO pathways and modulates dopamine, GABA, serotonin systems; promotes angiogenesis, fibroblast migration, tendon-to-bone healing in animal models.
Reference facts
- Also known as
- Body Protection Compound 157, PL 14736
- Category
- Healing & Tissue Repair
- Mechanism of action
- Up-regulates VEGF-R2 / NO pathways and modulates dopamine, GABA, serotonin systems; promotes angiogenesis, fibroblast migration, tendon-to-bone healing in animal models.
- Targets
- VEGF-R2 (indirect), NO synthesis, Multiple growth factor pathways
- Indications under research or approved
- Research only — tendon, ligament, GI ulcer, IBD models in animals
- Regulatory status (reference entry)
- Not FDA-approved. Removed from FDA 503A bulks list 2023.
- Half-life
- ~4 hours (oral, gastric stability)
- Sequence
- GEPPPGKPADDAGLV
- Sequence notes
- 15-residue partial sequence of human gastric juice protein BPC. Stable acetate or arginate salt commonly used in research.
- Molecular weight (Da)
- 1419
- Originator / sponsor
- Originally Diagen / Pliva (Croatian research)
- First reported
- 1991
- Origin
- Isolated from human gastric juice by Predrag Sikiric and colleagues at the University of Zagreb.
Primary References
- Sikiric et al., Curr Pharm Des 2014 (BPC-157 review)
- FDA 503A bulks list — BPC-157 nominated for category 2 (insufficient safety data)
Explore research articles about BPC-157
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.